{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T06:43:59Z","timestamp":1777099439147,"version":"3.51.4"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T00:00:00Z","timestamp":1761782400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T00:00:00Z","timestamp":1761782400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100022274","name":"Daiichi Sankyo Europe","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100022274","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ir J Med Sci"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s11845-025-04096-y","type":"journal-article","created":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T08:34:20Z","timestamp":1761813260000},"page":"2085-2094","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Lipid-lowering therapy treatment regimens in high- and very high-risk patients for the prevention of cardiovascular events: results from the Irish cohort of the multinational, observational SANTORINI study"],"prefix":"10.1007","volume":"194","author":[{"given":"Himanshu","family":"Rai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John Joseph","family":"Coughlan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"O\u2019Callaghan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Sheahan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ross","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Burke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eugene","family":"McFadden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dermot","family":"Nolan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roisin","family":"Colleran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abiola","family":"Hazeez-Agbaje","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kausik K.","family":"Ray","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberico L.","family":"Catapano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5224-6393","authenticated-orcid":false,"given":"Robert A.","family":"Byrne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"on behalf\u00a0of SANTORINI study investigators","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,30]]},"reference":[{"issue":"42","key":"4096_CR1","doi-asserted-by":"publisher","first-page":"2950","DOI":"10.1093\/eurheartj\/ehu299","volume":"35","author":"M Nichols","year":"2014","unstructured":"Nichols M, Townsend N, Scarborough P, Rayner M (2014) Cardiovascular disease in Europe 2014: epidemiological update. Eur Heart J 35(42):2950\u20132959. https:\/\/doi.org\/10.1093\/eurheartj\/ehu299","journal-title":"Eur Heart J"},{"key":"4096_CR2","doi-asserted-by":"publisher","unstructured":"Cholesterol Treatment Trialists C, Mihaylova B, Emberson J, Blackwell L, Keech A, Simes J et al (2012) The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 380(9841):581\u201390.https:\/\/doi.org\/10.1016\/S0140-6736(12)60367-5.","DOI":"10.1016\/S0140-6736(12)60367-5"},{"issue":"1","key":"4096_CR3","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","volume":"41","author":"F Mach","year":"2020","unstructured":"Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L et al (2020) 2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 41(1):111\u2013188. https:\/\/doi.org\/10.1093\/eurheartj\/ehz455","journal-title":"Eur Heart J"},{"issue":"39","key":"4096_CR4","doi-asserted-by":"publisher","first-page":"2999","DOI":"10.1093\/eurheartj\/ehw272","volume":"37","author":"AL Catapano","year":"2016","unstructured":"Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H et al (2016) 2016 ESC\/EAS guidelines for the management of dyslipidaemias. Eur Heart J 37(39):2999\u20133058. https:\/\/doi.org\/10.1093\/eurheartj\/ehw272. (2016\/08\/28)","journal-title":"Eur Heart J"},{"key":"4096_CR5","doi-asserted-by":"publisher","unstructured":"Vrablik M, Seifert B, Parkhomenko A, Banach M, Jozwiak JJ, Kiss RG et al (2021) Lipid-lowering therapy use in primary and secondary care in Central and Eastern Europe: DA VINCI observational study. Atherosclerosis 334:66\u201375. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2021.08.035","DOI":"10.1016\/j.atherosclerosis.2021.08.035"},{"key":"4096_CR6","doi-asserted-by":"publisher","unstructured":"Offiah G, O'Connor C, Kennedy C, Gallagher J, O'Connor P, McAdam B et al (2023) The DA VINCI study: is Ireland achieving ESC\/EAS guideline-directed LDL-C goals? Ir J Med Sci 192(3):1077\u201384. https:\/\/doi.org\/10.1007\/s11845-022-03050-6","DOI":"10.1007\/s11845-022-03050-6"},{"key":"4096_CR7","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.athplu.2021.08.003","volume":"43","author":"KK Ray","year":"2021","unstructured":"Ray KK, Haq I, Bilitou A, Aguiar C, Arca M, Connolly DL et al (2021) Evaluation of contemporary treatment of high- and very high-risk patients for the prevention of cardiovascular events in Europe - methodology and rationale for the multinational observational SANTORINI study. Atherosclerosis Plus 43:24\u201330. https:\/\/doi.org\/10.1016\/j.athplu.2021.08.003. (2021\/08\/13)","journal-title":"Atherosclerosis Plus"},{"key":"4096_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2023.100624","volume":"29","author":"KK Ray","year":"2023","unstructured":"Ray KK, Haq I, Bilitou A, Manu MC, Burden A, Aguiar C (2023) Treatment gaps in the implementation of LDL cholesterol control among high- and very high-risk patients in Europe between 2020 and 2021: the multinational observational SANTORINI study. Lancet Reg Health 29:100624. https:\/\/doi.org\/10.1016\/j.lanepe.2023.100624","journal-title":"Lancet Reg Health"},{"key":"4096_CR9","doi-asserted-by":"publisher","DOI":"10.1093\/eurjpc\/zwae199","author":"KK Ray","year":"2024","unstructured":"Ray KK, Aguiar C, Arca M, Connolly DL, Eriksson M, Ferrieres J et al (2024) Use of combination therapy is associated with improved LDL-cholesterol management: 1-year follow-up results from the European observational SANTORINI study. Eur J Prev Cardiol. https:\/\/doi.org\/10.1093\/eurjpc\/zwae199. (2024\/06\/11)","journal-title":"Eur J Prev Cardiol"},{"issue":"12","key":"4096_CR10","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1136\/heartjnl-2013-303640","volume":"99","author":"JA Dorresteijn","year":"2013","unstructured":"Dorresteijn JA, Visseren FL, Wassink AM, Gondrie MJ, Steyerberg EW, Ridker PM et al (2013) Development and validation of a prediction rule for recurrent vascular events based on a cohort study of patients with arterial disease: the SMART risk score. Heart 99(12):866\u2013872. https:\/\/doi.org\/10.1136\/heartjnl-2013-303640","journal-title":"Heart"},{"issue":"18","key":"4096_CR11","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1161\/01.cir.97.18.1837","volume":"97","author":"PW Wilson","year":"1998","unstructured":"Wilson PW, D\u2019Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB (1998) Prediction of coronary heart disease using risk factor categories. Circulation 97(18):1837\u20131847. https:\/\/doi.org\/10.1161\/01.cir.97.18.1837","journal-title":"Circulation"},{"issue":"9976","key":"4096_CR12","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1016\/S0140-6736(14)61368-4","volume":"385","author":"C Cholesterol Treatment Trialists","year":"2015","unstructured":"Cholesterol Treatment Trialists C, Fulcher J, O\u2019Connell R, Voysey M, Emberson J, Blackwell L et al (2015) Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet 385(9976):1397\u20131405. https:\/\/doi.org\/10.1016\/S0140-6736(14)61368-4","journal-title":"Lancet"},{"issue":"12","key":"4096_CR13","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1001\/jama.2016.13985","volume":"316","author":"MG Silverman","year":"2016","unstructured":"Silverman MG, Ference BA, Im K, Wiviott SD, Giugliano RP, Grundy SM et al (2016) Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis. JAMA 316(12):1289\u20131297. https:\/\/doi.org\/10.1001\/jama.2016.13985. (2016\/09\/28)","journal-title":"JAMA"},{"issue":"15","key":"4096_CR14","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1001\/jama.2018.2525","volume":"319","author":"EP Navarese","year":"2018","unstructured":"Navarese EP, Robinson JG, Kowalewski M, Kolodziejczak M, Andreotti F, Bliden K et al (2018) Association between baseline LDL-C level and total and cardiovascular mortality after LDL-C lowering: a systematic review and meta-analysis. JAMA 319(15):1566\u20131579. https:\/\/doi.org\/10.1001\/jama.2018.2525. (2018\/04\/21)","journal-title":"JAMA"},{"issue":"25","key":"4096_CR15","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","volume":"372","author":"CP Cannon","year":"2015","unstructured":"Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P et al (2015) Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 372(25):2387\u20132397. https:\/\/doi.org\/10.1056\/NEJMoa1410489","journal-title":"N Engl J Med"},{"key":"4096_CR16","doi-asserted-by":"publisher","unstructured":"Cholesterol Treatment Trialists C, Baigent C, Blackwell L, Emberson J, Holland LE, Reith C et al Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670\u201381. https:\/\/doi.org\/10.1016\/S0140-6736(10)61350-5.","DOI":"10.1016\/S0140-6736(10)61350-5"},{"issue":"16","key":"4096_CR17","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1016\/j.jacc.2010.09.082","volume":"57","author":"J Hsia","year":"2011","unstructured":"Hsia J, MacFadyen JG, Monyak J, Ridker PM (2011) Cardiovascular event reduction and adverse events among subjects attaining low-density lipoprotein cholesterol <50 mg\/dl with rosuvastatin. J Am Coll Cardiol 57(16):1666\u20131675. https:\/\/doi.org\/10.1016\/j.jacc.2010.09.082","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"4096_CR18","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1111\/ijcp.12881","volume":"70","author":"T McCormack","year":"2016","unstructured":"McCormack T, Dent R, Blagden M (2016) Very low LDL-C levels may safely provide additional clinical cardiovascular benefit: the evidence to date. Int J Clin Pract 70(11):886\u2013897. https:\/\/doi.org\/10.1111\/ijcp.12881","journal-title":"Int J Clin Pract"},{"issue":"18","key":"4096_CR19","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","volume":"376","author":"MS Sabatine","year":"2017","unstructured":"Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA et al (2017) Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 376(18):1713\u20131722. https:\/\/doi.org\/10.1056\/NEJMoa1615664","journal-title":"N Engl J Med"},{"issue":"22","key":"4096_CR20","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","volume":"379","author":"GG Schwartz","year":"2018","unstructured":"Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R et al (2018) Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med 379(22):2097\u20132107. https:\/\/doi.org\/10.1056\/NEJMoa1801174. (2018\/11\/08)","journal-title":"N Engl J Med"},{"issue":"8","key":"4096_CR21","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1111\/ijcp.12419","volume":"68","author":"A Diaz Rodriguez","year":"2014","unstructured":"Diaz Rodriguez A, Murga N, Camafort-Babkowski M, Lopez Peral JC, Ruiz E, Ruiz-Baena J et al (2014) Therapeutic inertia in hypercholesterolaemia is associated with ischaemic events in primary care patients. A case-control study. Int J Clin Pract 68(8):1001\u20131009. https:\/\/doi.org\/10.1111\/ijcp.12419","journal-title":"Int J Clin Pract"}],"container-title":["Irish Journal of Medical Science (1971 -)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11845-025-04096-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11845-025-04096-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11845-025-04096-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T16:30:53Z","timestamp":1767630653000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11845-025-04096-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,30]]},"references-count":21,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["4096"],"URL":"https:\/\/doi.org\/10.1007\/s11845-025-04096-y","relation":{},"ISSN":["0021-1265","1863-4362"],"issn-type":[{"value":"0021-1265","type":"print"},{"value":"1863-4362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,30]]},"assertion":[{"value":"4 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Professor Robert A. Byrne reports research funding to the institution from Abbott Vascular, Biosensors, Boston Scientific and Translumina. Professor Alberico L. Catapano has received research grant support to his institution from Amryt Pharma, Menarini and Viatris and has received honoraria, lecture fees from Akcea Therapeutics, Amarin, Amgen, Amryt Pharma, AstraZeneca, Daiichi Sankyo, Esperion, Ionis Pharmaceutical, Medscape Education, Menarini, Merck, Mylan, Novartis, Novo Nordisk, PeerVoice, Pfizer, Recordati, Regeneron, Sanofi, The Corpus and Viatris. Professor Kausik K. Ray reports honoraria for consulting, lectures from Abbott Laboratories, Amgen, Astra Zeneca, Bayer Healthcare Pharmaceuticals, Boehringer Ingelheim, Cargene, CRISPR, Daiichi Sankyo, Eli Lilly Company, Emendobio, Esperion, Kowa, New AmsterdamPharma, Novartis Corporation, Nodthera, GSK, Novo Nordisk, Pfizer, Regeneron, Sanofi, SCRIBE, Silence Therapeutics, and VAXXINITY. In addition, he has received research grant support to his institution from Amgen, Daiichi Sankyo, Sanofi, Regeneron and Ultragenix, plus stock options New Amsterdam Pharma, Scribe, Pemi 31. Abiola Hazeez-Agbaje is employed by Daiichi Sankyo Europe GmbH. All other authors declare no potential conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}